These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 17413689

  • 1. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
    Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS.
    AIDS; 2007 Mar 30; 21(6):685-92. PubMed ID: 17413689
    [Abstract] [Full Text] [Related]

  • 2. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct 30; 8(5):379-84. PubMed ID: 14640384
    [Abstract] [Full Text] [Related]

  • 3. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.
    Antivir Ther; 2004 Oct 30; 9(5):713-9. PubMed ID: 15535408
    [Abstract] [Full Text] [Related]

  • 4. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.
    HIV Med; 2007 Mar 30; 8(2):75-9. PubMed ID: 17352762
    [Abstract] [Full Text] [Related]

  • 5. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.
    J Infect Dis; 2004 Sep 15; 190(6):1046-54. PubMed ID: 15319852
    [Abstract] [Full Text] [Related]

  • 6. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR, Pediatric AIDS Clinical Trials Group 219/219C Study Team.
    Clin Infect Dis; 2008 Feb 15; 46(4):507-15. PubMed ID: 18199042
    [Abstract] [Full Text] [Related]

  • 7. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.
    HIV Med; 2007 Mar 15; 8(2):80-5. PubMed ID: 17352763
    [Abstract] [Full Text] [Related]

  • 8. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, Hogg RS, Montaner JS.
    J Infect Dis; 2006 Jan 15; 193(2):259-68. PubMed ID: 16362890
    [Abstract] [Full Text] [Related]

  • 9. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
    Lloyd-Smith E, Brodkin E, Wood E, Kerr T, Tyndall MW, Montaner JS, Hogg RS.
    AIDS; 2006 Feb 14; 20(3):445-50. PubMed ID: 16439879
    [Abstract] [Full Text] [Related]

  • 10. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.
    AIDS; 2008 Jul 11; 22(11):1305-12. PubMed ID: 18580610
    [Abstract] [Full Text] [Related]

  • 11. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.
    Wood E, Hogg RS, Yip B, Quercia R, Harrigan PR, O'Shaughnessy MV, Montaner JS.
    J Infect Dis; 2003 Nov 15; 188(10):1421-5. PubMed ID: 14624366
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E, Gutiérrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JS.
    AIDS; 2007 Jul 31; 21(12):1561-8. PubMed ID: 17630551
    [Abstract] [Full Text] [Related]

  • 14. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D, Berenguer J, Bellón JM, Miralles P, Cosin J, de Quiros JC, Conde MS, Muñoz-Fernández MA, Resino S.
    J Infect; 2008 Feb 31; 56(2):130-6. PubMed ID: 18192020
    [Abstract] [Full Text] [Related]

  • 15. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.
    AIDS; 2008 Nov 12; 22(17):2371-80. PubMed ID: 18981777
    [Abstract] [Full Text] [Related]

  • 16. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C, Muñoz A.
    Clin Infect Dis; 2007 Aug 01; 45(3):370-6. PubMed ID: 17599317
    [Abstract] [Full Text] [Related]

  • 17. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B, Navarro JO, Lamadrid-Figueroa H, Forsythe S, Trejo-Valdivia B.
    AIDS; 2008 Jul 01; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [Abstract] [Full Text] [Related]

  • 18. Mortality is influenced by locality in a major HIV/AIDS epidemic.
    Druyts EF, Rachlis BS, Lima VD, Harvard SS, Zhang W, Brandson EK, Strathdee SA, Montaner JS, Hogg RS.
    HIV Med; 2009 May 01; 10(5):274-81. PubMed ID: 19210694
    [Abstract] [Full Text] [Related]

  • 19. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G, l'Italian Seroconversion Study.
    Epidemiol Prev; 2003 May 01; 27(6):348-55. PubMed ID: 15058363
    [Abstract] [Full Text] [Related]

  • 20. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
    Kapogiannis BG, Soe MM, Nesheim SR, Sullivan KM, Abrams E, Farley J, Palumbo P, Koenig LJ, Bulterys M.
    Pediatrics; 2008 May 01; 121(5):e1229-39. PubMed ID: 18450865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.